Skip to main content
OpenTrials
Completed

NCT Number: NCT05614726

A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study

This randomized, placebo-controlled, double-blind study will determine the effect of daily supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e., The Center for Applied Health Sciences).

Subjects will attend three study visits. During Visit 1, subjects will be screened for participation [i.e., medical history, routine blood work, background baseline diet]. During Visits 2 and 3 subjects will complete questionnaires that assess their gastrointestinal health (e.g., abdominal discomfort/bloating, constipation, regularity, stool consistency). Visits 2 and 3 will correspond to before (week 0) and after six weeks of supplementation, respectively, with the probiotic dietary supplement or placebo.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Center for Applied Health Sciences

Canfield, Ohio, 44406, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all participants were required to be between 30-60yr
  • score ≥12 on the GSRS
  • have a body mass ≥120 pounds (54.5kg)
  • body mass index (BMI) between 20.0-34.99kg/m2
  • normotensive (<140/<90mmHg)
  • normal resting heart rate (<90bpm)

Exclusion criteria

  • Female participants who were pregnant or nursing
  • history of unstable or new-onset cardiovascular or cardiorespiratory disease;
  • stroke, diabetes, or other endocrine disorder;
  • use of any nutritional supplement known to alter the gut microbiota/microflora;
  • use of probiotic supplements or prebiotic supplements in the previous 4 weeks and for the duration of the study;
  • use of any antibiotics, antifungals, antivirals, or antiparasitic within 8 weeks of the start of the study or throughout the study;
  • any changes in diet within 4 weeks of study start date or throughout study duration;
  • if the participant was unwilling to abstain from gut altering supplements for the study;
  • malignancy in the previous 5yr except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin);
  • prior gastrointestinal bypass surgery (i.e., Lapband);
  • any known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism [e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU)];
  • any chronic inflammatory condition/disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.);
  • known sensitivity to any ingredient in the test formulations as listed in the certificates of analysis.
  • currently participating in another research study with an investigational product or had participated in another research study in the past 30 days
  • any other diseases/conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

Treatment and study plan

575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase

Dietary Supplement

A multi-strain probiotic blend

Primary outcomes

  1. Flatulence (gas)

    Time frame: Change from baseline to 6 weeks.

    Flatulence (gas) as measured by a 10 cm visual analogue scale, where higher values represent greater flatulence.

  2. Gastro-intestinal bloating

    Time frame: Change from baseline to 6 weeks.

    Gastro-intestinal bloating as measured by a 10 cm visual analogue scale, where higher values represent greater bloating.

  3. Abdominal discomfort

    Time frame: Change from baseline to 6 weeks.

    Abdominal discomfort as measured by a 10 cm visual analogue scale, where higher values represent greater discomfort.

  4. Gastrointestinal Symptom Rating Scale (GSRS)

    Time frame: Change from baseline to 6 weeks.

    Gastrointestinal problems as measured by the GSRS questionnaire, where higher values represent increased severity of gastrointestinal problems.

Secondary outcomes

  1. Stool consistency

    Time frame: Change from baseline to 6 weeks.

    Stool consistency as measured by a 10 cm visual analogue scale, where higher values represent harder stools.

  2. Stool regularity

    Time frame: Change from baseline to 6 weeks.

    Stool regularity as measured by a 10 cm visual analogue scale, where higher values represent more regular stools.

  3. Constipation

    Time frame: Change from baseline to 6 weeks.

    Constipation as measured by a 10 cm visual analogue scale, where higher values represent more greater constipation.

Other outcomes

  1. Short Form Health Survey (SF-36)

    Time frame: Change from baseline to 6 weeks.

    Health status as measured with the SF-36 questionnaire, where scores range from 0 to 100, and higher values represent better health status.

Sponsors and collaborators

Lead sponsor

The Center for Applied Health Sciences, LLC

Industry

Collaborators

  • Biohm Health, LLC

Registry information

Official study title

Effects of a Probiotic Supplement on Gastrointestinal Symptoms and Microbiome Modulation

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Nov 14, 2022
Registry last updated
Nov 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.